# Veeva Systems Inc. (VEEV) stock news and updates

As of November 16, 2026. Source: https://www.clearthesis.ai/updates/VEEV

## Our view on the Veeva Systems Inc. investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/VEEV

## Latest updates on Veeva Systems Inc.

### Wells Fargo sets a $400 target for Veeva

*November 16, 2026 · analyst · significance: notable · signal: positive*

Wells Fargo kept its overweight rating, a sign they expect the stock to perform better than the broader market. Their new $400 price target is about 30 percent higher than where the stock trades today and sits well above the average analyst target of $307. This confidence comes as the company moves its customers from Salesforce technology onto its own platform, Vault CRM. If successful, this shift should help the business keep more of every dollar it earns by removing the need to pay licensing fees to an outside partner.

Sources: [Wells Fargo](https://www.streetinsider.com/Analyst+Comments/Veeva+Systems+%28VEEV%29+PT+Raised+to+%24400+at+Wells+Fargo/27325882.html)

### BTIG sets a $360 price target for Veeva

*November 9, 2026 · analyst · significance: minor · signal: positive*

BTIG set a new price target of $360 for the software maker on Monday. This is notably higher than the average analyst target, which currently sits at $303, right where the stock is trading today. Veeva is in the middle of moving its customers from Salesforce technology to its own platform to save on licensing costs. This higher target suggests confidence that the shift is progressing well and will lead to higher profit margins over time.

Sources: [BTIG](https://www.streetinsider.com/Analyst+Comments/Veeva+Systems+%28VEEV%29+PT+Raised+to+%24360+at+BTIG/27310105.html)

### Global drugmaker UCB commits to Veeva's new CRM platform

*November 4, 2026 · news · significance: notable · signal: positive*

UCB has signed on to use Veeva's new Vault CRM, a platform designed to help drug companies manage their sales and customer relationships. This is a key win for Veeva as it works to move its entire customer base off of Salesforce's technology and onto its own in-house system. By moving customers to its own platform, Veeva can stop paying licensing fees to Salesforce, which should leave the company with more profit from every dollar it earns. This deal shows that large, global drugmakers are willing to make the switch, supporting the idea that Veeva can successfully transition its customers without losing them to rivals.

Sources: [PRNewsWire](https://www.prnewswire.com/news-releases/ucb-selects-veeva-vault-crm-302928843.html)

### Major drugmakers adopt Veeva's new AI and data tools

*November 2, 2026 · product · significance: notable · signal: positive*

At its recent summit, Veeva showcased its new AI tools alongside several of the world's largest pharmaceutical companies. Leaders from firms like AstraZeneca, Roche, and Novo Nordisk are adopting these innovations to automate complex tasks for their sales teams and better manage their data. This is a key step in Veeva's plan to move customers onto its own proprietary platform. By proving that industry giants are willing to use its new AI features, Veeva is showing it can deepen its grip on the life sciences market while reducing its reliance on outside technology partners. This shift is vital for the company to grow its profit margins over the long term.

Sources: [PRNewsWire](https://www.prnewswire.com/news-releases/le-veeva-summit-presente-les-innovations-en-ia-et-en-donnees-qui-font-progresser-le-commerce-des-agents-302923910.html)

### Barclays raised its target for Veeva to $360

*October 19, 2026 · analyst · significance: minor · signal: positive*

Barclays raised its price target for Veeva to $360, up from $315. This move puts the firm's target well above the average analyst estimate of $294. While the stock has risen recently, this change suggests analysts are becoming more confident in the company's ability to grow as it moves customers onto its own software platform.

Sources: [Barclays](https://thefly.com/ajax/news_get.php?id=4443668)

## Veeva Systems Inc. earnings

In Q2 2027, reported on August 26, 2026, Veeva Systems Inc. posted earnings of $2.35 per share against $2.23 expected, and revenue of $928.0 million against $905.4 million expected.

The next earnings report is expected on December 3, 2026. Analysts expect $2.34 per share. Revenue is expected around $935.2 million.

What to watch: The number of customers live on Vault CRM, as this shows how quickly the company is moving clients off Salesforce technology to boost its own profit margins.

## Recent analyst activity on VEEV

- November 11, 2026: Wells Fargo Kept rating at Overweight, set target. Price target: $400.00.
- November 9, 2026: Truist Securities Kept rating at Buy.
- November 9, 2026: BTIG Kept rating at Buy, set target. Price target: $360.00.
- November 9, 2026: Canaccord Genuity Kept rating at Hold.
- November 6, 2026: Jefferies Kept rating at Buy.
- November 6, 2026: Needham Kept rating at Buy.

## What's ahead for Veeva Systems Inc.

- December 3, 2026: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/VEEV
